N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide an operational update on its development
N4 Pharma PLC (AIM:N4P) Work Programme Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce a further update on its recent
N4 Pharma PLC (AIM:N4P) Work Programme Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce an update on its current work
N4 Pharma PLC (AIM: N4P) Final Results
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce its audited results for the year
Nigel Theobald, Chief Executive Officer N4 Pharma PLC (LON:N4P) Interview
N4 Pharma Plc (AIM: N4P), provide details of its work plan following the encouraging data from its oncology research as announced on 13 December 2021. The company sounded very positive
Yourgene Health PLC (YGEN.L) DHSC contract award for COVID Winter surge testing
Third contract awarded under PHE National Microbiology Framework Agreement
Poolbeg Pharma PLC (POLB.L) PredictViral™ Patent update
14 October 2021 – Poolbeg Pharma (AIM: POLB), ‘Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, provides an update on new
Poolbeg Pharma plc (POLB.L) RNA sequencing ahead of pioneering AI analysis programme
7 October 2021 – Poolbeg Pharma (AIM: POLB), Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has partnered with leading global
Oxford Nanopore valued at £4.93bn as shares soar in London debut
Investors snapped up shares in biotech company Oxford Nanopore after its IPO this morning, with the shares soaring 45 per cent.
MyHealthChecked PLC (MHC.L) Statement re. COVID-19 testing
MyHealthChecked Plc (AIM: MHC), the consumer home-testing healthcare company, notes the recent Government statement regarding measures to simplify international travel.
Yourgene Health PLC (YGEN.L) Re DHSC contract to support COVID-19 surge testing
Manchester, UK 10 September 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that a Contract Award Notice has been published in relation to its contract with the
